Search results with tag "Oedema"
COVID-19 Moderna Vaccine Analysis Print
assets.publishing.service.gov.ukEye oedema 1 0 Eye pain 285 0 Eye swelling 110 0 Eyelids pruritus 1 0 Ocular discomfort 8 0 Periorbital oedema 3 0 ... Acute macular neuroretinopathy 1 0 Serous retinopathy 1 0 Scleral infections, irritations and inflammations Episcleritis 5 0 Structural change, deposit and degeneration of eye NEC
JOINT FORMULARY FOR HULL AND EAST RIDING OF …
www.hey.nhs.ukmacular oedema secondary to inherited retinal diseases (specialist prescriber for short term post-op use) 2.3 ANTI-ARRHYTHMIC DRUGS See also 2.4 and 2.6.2 2.3.2 Drugs for arrhythmia Amiodarone “SCF pending” Dronedarone Disopyramide, Flecainide, Propafenone, Mexiletine 2.4 BETA-ADRENOCEPTOR BLOCKING DRUGS 2.4 Hypertension/angina/ arrhythmias
Information for Patients Undergoing YAG Laser Capsulotomy
www.bfwh.nhs.ukCystoid Macular Oedema (CMO) This is a relatively rare complication. CMO is the accumulation of fluid at the back of the eye (the . retina) in the central area (the macula) due to leakage from capillaries. This in turn may cause a drop in central reading vision but can usually be treated should it occur. SAMPLE
Patient information Anti-VEGF intravitreal injection treatment
www.moorfields.nhs.ukMacular oedema is swelling and thickening of the macula. The macula is a small area in the centre of the retina that contains a rich collection of nerve cells sensitive to light, fine detail, and colour. The vein block causes the blood pressure to increase in the small retinal blood vessels which causes them to bleed
Steroids and the eye - RNIB
www.rnib.org.uk(i) Macular oedema with fluid blisters in the outer retina may develop in susceptible individuals. This is termed central serous chorio-retinopathy. (ii) CSCR is more common in middle-aged males with Type-A personalities and psychological stress and may occur in association with use of topical, systemic or inhaled steroids.
Diabetic Retinopathy Guidelines - RCOphth
www.rcophth.ac.ukIn addition macular oedema . 7 is determined as absent or present and further sub classified on the basis of involvement of the centre of the macula. 1.2.2 Population screening classifications The National Screening Committee (NSC)6 has adopted a classification for use in
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euLucentis and laser photocoagulation in DME and in macular oedema secondary to BRVO There is some experience of Lucentis administered concomitantly with laser photocoagulation (see section 5.1). When given on the same day, Lucentis should be administered at least 30 minutes after laser photocoagulation.
Chronic Complications - World Health Organization
www2.wpro.who.intType 2 diabetic patients can develop both proliferative and non-proliferative diabetic retinopathy, although it is the latter type complicated by macular oedema that …